We provide viable solutions.
With the uncertainty surrounding Brexit, proper monitoring and planning are essential for ensuring that your studies continue to unfold seamlessly. We are prepared to help you find the best course of action.
To stay abreast of evolving Brexit developments we created the ACM Global Brexit Response Team (ACM-BRT). Our experts have undergone extensive training to address potential changes in customs procedures that may occur after the United Kingdom (UK) leaves the European Union (EU).
The ACM-BRT has worked to develop comprehensive measures to reduce potential delays in sample shipments and to reduce the challenges that Brexit could have on your clinical trial. We are here as your partner, to answer all of your questions about the impact of Brexit on our business processes so you can feel confident in your decision to make ACM your preferred central lab.
While the latest deadline for the UK to leave the EU draws near, the outcome of this transition remains unsettled. At ACM Global Laboratories, our first priority is to ensure the safe and timely shipping of your clinical trial specimens. When you partner with ACM and our dedicated ACM-BRT you will be working with a team that is continually assessing ways to reduce the risks that Brexit could have on the success of your clinical trial.
Since 2016, as Brexit developments have unfolded, the ACM-BRT has continued to closely monitor the situation and proactively keep our customers updated on all changes that take place to ensure all stakeholders have the real-time information that they need.
The ACM-BRT is dedicated to ensuring that your clinical trials achieve key milestones and you keep your submission timeline goals, meeting investor and patient expectations of delivering lifesaving therapies to market. Our subject matter experts that form the ACM-BRT are transparent and available to offer you proactive solutions regardless of the ultimate Brexit outcome.
Based on input from current customers that partner with ACM as their central lab of choice during the Brexit transition, we have identified and provided feedback to several frequently asked questions (FAQs). We encourage you to contact us with your specific questions and engage with our ACM-BRT for a no-cost evaluation and proposed solutions for how we would support your clinical trial during and after the Brexit transition period.
The ACM-BRT is fully prepared to respond to any potential Brexit outcomes in 2020 and is equipped to provide a solution to any new developments as they arise. Our mission is to continue safeguarding your studies and partner with you in order to keep you updated as the Brexit landscape continues to evolve. Your projects are a top priority and will continue keeping you abreast of information. Please contact us at your convenience if we may answer any additional questions or concerns about the Brexit transition.
Please know that our company and the ACM-BRT are ready to provide clients with continuing services regardless of any possible challenges related to Brexit. To address your individual questions about our company’s response to the Brexit situation and how we have planned for the transition, please contact us at your convenience. Your projects are a top priority and will continue keeping you abreast of information.